» Articles » PMID: 33646178

Oral Dysbiosis and Inflammation in Parkinson's Disease

Abstract

Background: Oral microbiota has largely escaped attention in Parkinson's disease (PD), despite its pivotal role in maintaining oral and systemic health.

Objective: The aim of our study was to examine the composition of the oral microbiota and the degree of oral inflammation in PD.

Methods: Twenty PD patients were compared to 20 healthy controls. Neurological, periodontal and dental examinations were performed as well as dental scaling and gingival crevicular fluid sampling for cytokines measurement (interleukine (IL)-1β, IL-6, IL-1 receptor antagonist (RA), interferon-γ and tumor necrosis factor (TNF)-α). Two months later, oral microbiota was sampled from saliva and subgingival dental plaque. A 16S rRNA gene amplicon sequencing was used to assess bacterial communities.

Results: PD patients were in the early and mid-stage phases of their disease (Hoehn & Yahr 2-2.5). Dental and periodontal parameters did not differ between groups. The levels of IL-1β and IL-1RA were significantly increased in patients compared to controls with a trend for an increased level of TNF-α in patients. Both saliva and subgingival dental plaque microbiota differed between patients and controls. Streptococcus mutans, Kingella oralis, Actinomyces AFQC_s, Veillonella AFUJ_s, Scardovia, Lactobacillaceae, Negativicutes and Firmicutes were more abundant in patients, whereas Treponema KE332528_s, Lachnospiraceae AM420052_s, and phylum SR1 were less abundant.

Conclusion: Our findings show that the oral microbiome is altered in early and mid-stage PD. Although PD patients had good dental and periodontal status, local inflammation was already present in the oral cavity. The relationship between oral dysbiosis, inflammation and the pathogenesis of PD requires further study.

Citing Articles

Potential Biomarkers and Treatment of Neuroinflammation in Parkinson's Disease.

Zhao Z, Fu Q, Guo X, He H, Yang G Actas Esp Psiquiatr. 2025; 53(1):181-188.

PMID: 39801407 PMC: 11726199. DOI: 10.62641/aep.v53i1.1779.


Microbiota Orchestra in Parkinson's Disease: The Nasal and Oral Maestros.

Rei N, Grunho M, Mendes J, Fonseca J Biomedicines. 2024; 12(11).

PMID: 39594984 PMC: 11591639. DOI: 10.3390/biomedicines12112417.


The Connection Between the Oral Microbiota and the Kynurenine Pathway: Insights into Oral and Certain Systemic Disorders.

Kis-Gyorgy R, Kortesi T, Anicka A, Nagy-Grocz G Curr Issues Mol Biol. 2024; 46(11):12641-12657.

PMID: 39590344 PMC: 11593024. DOI: 10.3390/cimb46110750.


Can salivary and skin microbiome become a biodetector for aging-associated diseases? Current insights and future perspectives.

Nurkolis F, Utami T, Alatas A, Wicaksono D, Kurniawan R, Ratmandhika S Front Aging. 2024; 5:1462569.

PMID: 39484071 PMC: 11524912. DOI: 10.3389/fragi.2024.1462569.


Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease.

Stagaman K, Kmiecik M, Wetzel M, Aslibekyan S, Sonmez T, Fontanillas P Commun Med (Lond). 2024; 4(1):209.

PMID: 39443634 PMC: 11499922. DOI: 10.1038/s43856-024-00630-8.


References
1.
Zekeridou A, Giannopoulou C, Cancela J, Courvoisier D, Mombelli A . Effect of initial periodontal therapy on gingival crevicular fluid cytokine profile in subjects with chronic periodontitis. Clin Exp Dent Res. 2018; 3(2):62-68. PMC: 5719814. DOI: 10.1002/cre2.61. View

2.
Wade W . The oral microbiome in health and disease. Pharmacol Res. 2012; 69(1):137-43. DOI: 10.1016/j.phrs.2012.11.006. View

3.
Schloss P, Westcott S, Ryabin T, Hall J, Hartmann M, Hollister E . Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol. 2009; 75(23):7537-41. PMC: 2786419. DOI: 10.1128/AEM.01541-09. View

4.
Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Bjorklund T . Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. 2014; 128(6):805-20. DOI: 10.1007/s00401-014-1343-6. View

5.
Lewis S, Heaton K . Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997; 32(9):920-4. DOI: 10.3109/00365529709011203. View